India, July 3 -- Shares of OS Therapies Inc. (OSTX) were gaining around 12% in the pre-market activity after the company announced Thursday that it was granted an End of Phase 2 Meeting by the United States Food & Drug Administration. The meeting would review the OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.
The clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company said it expects the meeting to occur in the third quarter of 2025.
The End of Phase 2 Meeting marks a pivotal point in the drug development process, and a significant milestone towards market access.
OST-HER2 is an immunotherapy for osteosarcoma that uses a HER2-bioengineered form...